
Opinion|Videos|August 23, 2024
A Cure in Sight: Who We Are
Author(s)Nathan L. Scott, M.D., Melody Burchett
Melody Burchett discusses her journey with uveal melanoma and the formation of A Cure in Sight. This program was made possible with support from Immunocore.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the focus of your organization, A Cure in Sight?
Advertisement
Related to this article

A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.

Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.

HealthCare.gov open enrollment runs Nov. 1, 2026, to Jan. 15, 2027, and the 2027 out-of-pocket ceiling rises to $12,000. Here's what people with cancer should check before picking a plan.

After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).

For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.

A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.

After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the kind of friend she once needed.
Advertisement
Advertisement

